InvestorsHub Logo
Followers 5
Posts 528
Boards Moderated 0
Alias Born 07/16/2013

Re: fbg0316 post# 92195

Friday, 02/08/2019 5:49:34 AM

Friday, February 08, 2019 5:49:34 AM

Post# of 108191
That may be a fair statement, although it may be a little premature to come to that conclusion. However it may play out that way and possibly show consistency from what we have seen in the past.

IMO that the future of this company probably lies in the design of AIM2CERV; which thankfully the company had the foresight to design the phase 3 in this fashion. Here is an excerpt from the AIM2CERV webpage:

The study is for women living with high-risk, locally-advanced cervical cancer (HRLACC) which is a cervical cancer that has an increased risk for returning following treatment with chemotherapy and radiation therapy. Your doctor can help determine if you meet the requirements for the study.

This study is being done to determine whether ADXS11-001, when taken after the completion of chemotherapy and radiation therapy, can help you live longer without the disease returning.

I am not a trained financial professional, and all posts are my bar stool amateur opinion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News